- Telehealth Visits
- Insurance plan information
Scott S. Zamvil, MD, PhD
Neurology- Telehealth Visits
- Insurance plan information
Scott S. Zamvil, MD, PhD
Neurology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Scott Zamvil is a neurologist and immunologist who specializes in treating multiple sclerosis and neuromyelitis optica. His research focuses on developing novel treatments for these autoimmune diseases.
Zamvil earned his medical degree and a doctorate in microbiology and immunology from Stanford University. He then completed a residency in internal medicine at Stanford University and a residency in neurology at Brigham and Women's Hospital. Before coming to UCSF, he was a neurologist at Brigham and Women's Hospital.
Zamvil is a board member of the International Society of Neuroimmunology. He is also an adviser for America's Committee for Treatment and Research in Multiple Sclerosis. He serves as deputy editor of the journal Neurology: Neuroimmunology & Neuroinflammation.
Education & training
Board certification
- Neurology, American Board of Psychiatry and Neurology
Residency
- Neurology, Brigham & Women's Hospital
- Internal Medicine, Stanford University Internal Medicine Residency
Internship
- Internal Medicine, Pacific Presbyterian (now CPMC)
Degree
- MD, Stanford University School of Medicine
My expertise
Specialties
Conditions
- Neuromyelitis Optica (NMO)
- Multiple Sclerosis
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%22706%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%22706%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.